Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

QRxPharma Limited (QRx Pharma)

12,611,103

ABN

16 102 254 151

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Fully paid ordinary shares (Shares)

- 2 Number of ⁺securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

As per fully paid ordinary shares in QRxPharma Limited

Do the ⁺ securities rank equally in all	Yes			
respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?				
 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 				
Issue price or consideration	\$0.85			
Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The net proceeds will be used to fund a Phase 3 labelling claim study that will enable the Company to make marketing and advertising claims in Europe and the US for MoxDuo® IR an immediate release Dual-Opiod® pain therapy.			
	The funds will also be used to support the Company as it files its New Drug Application (NDA) with the US Food and Drug Administration (FDA) and advances its Marketing Authorisation Application (MAA) in Europe for MoxDuo® IR in CY2011, and, to further progress the development programs of MoxDuo® CR(controlled release) and MoxDuo® IV (intravenous).			
Dates of entering ⁺ securities into uncertificated holdings or despatch of certificates	9 November 2010			
	Number	+Class		
Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	119,002,353	Ordinary Shares		
	 with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Dates of entering *securities into uncertificated holdings or despatch of certificates Number and *class of all *securities quoted on ASX (<i>including</i> the securities in clause 	with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they do • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.85 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) The net proceeds will be us labelling claim study that by to make marketing and adv and the US for MoxDuo® Dual-Opiod® pain therapy The funds will also be used as it files its New Drug Ap US Food and Drug Admini advances its Marketing Au (MAA) in Europe for Mox to further progress the deve MoxDuo® CR(controlled r (intravenous). Dates of entering *securities into uncertificated holdings or despatch of certificates 9 November 2010 Number and *class of all *securities quoted on ASX (including the securities in clause 119,002,353		

⁺ See chapter 19 for defined terms.

	Number	⁺ Class
9. Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	295,000	Options with an exercise price of \$1.26 and an expiry date of 24 March 2014;
	402,726	Options with an exercise price of \$1.42 and expiry date of 31 March 2014;
	2,013,630	Options with an exercise price of \$1.00 and expiry date of 14 April 2014;
	1,448,450	Options with an exercise price of \$2.00 and expiry date of 25 May 2014;
	552,726	Options with an exercise price of \$1.00 and expiry date of 25 May 2014;
	50,000	Options with an exercise price of \$1.70 and expiry date of 1 September 2014;
	75,000	Options with an exercise price of \$1.45 and expiry date of 1 October 2014;
	50,000	Options with an exercise price of \$1.34 and an expiry date of 9 October 2014;
	25,000	Options with an exercise price of \$1.27 and an expiry date of 25 October 2014;
	200,000	Options with an exercise price of \$1.11 and an expiry date of 1 January 2015;
	600,000	Options with an exercise price of \$1.05 and an expiry date of 1 April 2015;
	75,000	Options with an exercise price of \$1.04 and an expiry date of 1 April 2015;
	50,000	Options with an exercise price of \$0.60 and an expiry date of 1 October 2015;
	295,000	Options with an exercise price of \$0.20 and an expiry date of 1 January 2016;
	467,500	Options with an exercise price of \$0.65 and an expiry date of 31 August 2016;
	150,000	Options with an exercise price of \$0.90 and an expiry date of 1 October 2016;
	300,000	Options with an exercise price of \$1.12 and an expiry date of 16 November 2016;
	100,000	Options with an exercise price of \$0.78 and an expiry date of 1 January 2017;
	565,000	Options with an exercise price of \$0.84 and an expiry date of 17 February 2017;

	Number	+Class
9. Number and ⁺ class of all	225,000	Options with an exercise price of \$1.15 and
⁺ securities not quoted on ASX		an expiry date of 1 July 2017;
(including the securities in clause		
2 if applicable) (continued)	50,000	Options with an exercise price of \$0.95 and an expiry date of 24 August 2017;
	150,000	Options with an exercise price of \$0.93 and an expiry date of 4 October 2017.
	L	

⁺ See chapter 19 for defined terms.

		Number	+Class
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		

Part 2 - Bonus issue or pro rata issue – Not Applicable

11	Is security holder approval required?	
12	Is the issue renounceable or non- renounceable?	
13	Ratio in which the ⁺ securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	*Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	

23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺security holders If the issue is contingent on 25 ⁺security holders' approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do ⁺security holders sell their entitlements in full through a broker? 31 How do +security holders sell part of their entitlements through a broker and accept for the balance? 32 How do +security holders dispose of their entitlements (except by sale through a broker)? 33 ⁺Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities (*tick one*)

⁺ See chapter 19 for defined terms.

(a)	\square	Securities described in Part 1
(b)		All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories 1 1,000 1,001 5,000 5,001 10,000 5,001 100,000 100,001 100,000 100,001 and over
- 37

35

A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

- 38 Number of securities for which ⁺quotation is sought
- 39 Class of +securities for which quotation is sought

h	

40 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?

If the additional securities do not rank equally, please state:


- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in clause 38)

+Class	
	+Class



Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

C. J. Campbell

Sign here:

Company Secretary

..... Date: 9 November 2010

Print name:

Chris J Campbell

⁺ See chapter 19 for defined terms.